BREATH: Biomarkers for Respiratory diseases detected in Exhaled Air through a new Technological instrument for research and Healthcare markets.

Informations projet

BREATH

N° de convention de subvention: 740460

DOI

10.3030/740460

Projet clôturé

Date de signature de la CE 15 Novembre 2016

Date de début 1 Novembre 2016

Date de fin 30 Avril 2017

Financé au titre de

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology

Coût total

€ 71 429,00

Contribution de l’UE

€ 50 000,00

Coordonné par

PEXA AB
Sweden

Periodic Reporting for period 1 - BREATH (BREATH: Biomarkers for Respiratory diseases detected in Exhaled Air through a new Technological instrument for research and Healthcare markets.)

Période du rapport: 2016-11-01 au 2017-04-30

Résumé du contexte et des objectifs généraux du projet

This project aims to accelerate the introduction of the BREATH technology in the lung research market with the aim to move into hospitals as a standard piece of diagnostic equipment. BREATH is the first non-invasive device which samples the small airways to collect biomarkers which are present in the early stages of many significant respiratory diseases such as lung cancer and asthma.
The symptoms of these tend not to appear until the disease has already reached an advanced stage and there is no way of detecting it at an early stage. These often begin with pathological changes within the small airways, referred to as the “silent zone”, due to the difficulty of accessing it. Research studies on the pathological changes and biomarkers (such as cells and proteins) of lung diseases have been slowed. However, these are essential to improve diagnoses and treatments. The lung research field needs a device capable of probing these zones while reliably and efficiently collecting samples from a large range of people which can be analysed.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

We have verified the technical, commercial and financial feasibility of the BREATH project. We have performed an in-depth market analysis which has shown us that we are the only technology capable of taking samples of the small airway, and are poised to exploit a huge gap in the lung research market. We have undertaken a detailed risk analysis and provided mitigation measures to ensure the project will continue on schedule. We have also prepared a detailed work plan with the specific tasks needed for the completion of the phase 2 project. Finally, we have assessed the financial feasibility of the BREATH project with the outcomes, indicating a positive outlook.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

Our primary target clients are research institutions and pharmaceutical companies, who are undertaking lung research to assist in the diagnosis or treatment of lung diseases, which comprises over 10,000 potential clients. After the BREATH project, roll-out is foreseen in Europe and North America by 2023 with annual sales revenues being €48.4M by 2024.
It will reduce the cost (6 times) and time (10 times) associated with lung research while providing the necessary functionality to undertake research which is currently not possible with conventional techniques. By allowing the discovery and validation of key biomarker relating to key lung diseases, BREATH will allow the quicker diagnosis and better treatment of these diseases, a significant benefit for our customers and the public.

breath-img-2.png

breath-img-1.png